According to the International Diabetes Federation, there are currently 363 million adults who are suffering from diabetes. By 2045, that number is expected to skyrocket to a deeply concerning 700 million. To help serve and protect all of those people, Abbott has released the innovative FreeStyle Libre 3 System.
On September 28, Abbott announced that this Continuous Glucose Monitoring (CGM) system was given the European CE mark of approval for people ages 4 and up with diabetes. According to Abbott, this “much anticipated” FreeStyle Libre 3 features “the world’s smallest, thinnest glucose sensor (about the size of two stacked U.S pennies)” for discreet monitoring without a fingerstick.
How it works
The system includes many of the well-known benefits of its predecessor, the FreeStyle Libre 2, such as 14-day accuracy and optional glucose alarms. “People living with diabetes are at the center of our design process,” said Jared Watkin, Senior Vice President of Diabetes Care for Abbott. He also shares that they “made our next-generation technology even more discreet for a better user experience to make managing Diabetes as easy and seamless as possible.”
In addition to these respected and time-tested features, the Freestye Libre 3 includes some very helpful new benefits. According to Abbott, such improvements include “continuous real-time glucose readings automatically delivered to a person’s smartphone every minute and a sensor that’s easy to apply with a one-piece applicator.”
Quality and Affordability
The Freestyle Libre 3 is more affordable and environmentally-friendly than its competitors. As noted in Abbott’s press release, it reduces the “system’s total volume by more than 70%”. It was also designed to “be more sustainable for the environment, including a 42% reduction in plastic use and 43% decrease in carton paper.” The system’s price has also been frozen to the same cost as previous generations to make it more accessible to the public.
Watkin has shared their determination as a company to keep the bar high in terms of innovation while being cost-friendly. After having received approval from the U.S Food and Drug Administration and CE marks on several products, Abbott is on a roll and plans to make sure everyone can get access to their possibly life-saving system.
Since releasing its first disposable glucose monitor in 2014, Abbott has stayed true to its message that “all people should have access to high-quality, accurate, and affordable diabetes technologies.” The company promises a bright future for those living with diabetes and plans to launch the FreeStyle Libre 3 system in Europe in the coming months.
YouTube: FreeStyle Libre 3 System Receives CE Mark
Photo credits: The images are owned by Abbott and have been provided for press usage.
Source: International Diabetes Federation